Publication
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugALK Inhibitor TAE684civic_curation1.00
- drugCrizotinibcivic_curation1.00
- drugForetinibcivic_curation1.00
- geneROS1civic_curation1.00
- variantROS1 Fusioncivic_curation1.00
- variantROS1 G2032Rcivic_curation1.00
- variantROS1 G2101Acivic_curation1.00
- variantROS1 L2026Mcivic_curation1.00
- variantROS1 L2155Scivic_curation1.00
Curated evidence
Evidence citing this paper (8)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25688157
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ROS1 G2032R1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | — | submitted | EID4614In a phase 1 study (NCT00585195), a stage IIIA pulmonary adenocarcinoma patient with acquired crizotinib resistance harbored a CD74-ROS1 gene rearrangement (a known sensitizing alteration to crizotini… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 Fusion + ROS1 G2032R2 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID1254ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| Foretinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1255Ba/F3 cells expressing CD74–ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 Fusion + ROS1 G2101A2 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | 2 | accepted | EID1259Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| Foretinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1260Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib. PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 Fusion + ROS1 L2026M2 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | 2 | accepted | EID1257Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity t… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| Foretinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1258Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74–ROS1. This is in contrast to the increased resistance to crizotin… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 Fusion + ROS1 L2155S1 | ||||||||
| ALK Inhibitor TAE684 + Crizotinib + ForetinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID1256The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib … (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |